1-3 of 3
Nehal Lakhani
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies

Melissa Johnson, Anthony El-Khoueiry, Navid Hafez, Nehal Lakhani, Hirva Mamdani, Jordi Rodon, Rachel E. Sanborn, Javier Garcia-Corbacho, Valentina Boni, Mark Stroh, Alison L. Hannah, Song Wang, Henry Castro, Alexander Spira
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (16): 4521–4530.
https://doi.org/10.1158/1078-0432.CCR-21-0194
Published: 15 August 2021
View article titled, Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies
Open the PDF for Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies in another window
Includes: Supplementary data
Journal Articles

First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors

Michael L. Maitland, Jasgit C. Sachdev, Manish R. Sharma, Victor Moreno, Valentina Boni, Shivaani Kummar, Erica Stringer-Reasor, Nehal Lakhani, Allison R. Moreau, Dawei Xuan, Ray Li, Eric L. Powell, Amy Jackson-Fisher, Michelle Bowers, Shilpa Alekar, Xiaohua Xin, Anthony W. Tolcher, Emiliano Calvo
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4511–4520.
https://doi.org/10.1158/1078-0432.CCR-20-3757
Published: 15 August 2021
View article titled, First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors
Open the PDF for First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

ANG1005, a Brain-Penetrating Peptide–Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases

Priya Kumthekar, Shou-Ching Tang, Andrew J. Brenner, Santosh Kesari, David E. Piccioni, Carey Anders, Jose Carrillo, Pavani Chalasani, Peter Kabos, Shannon Puhalla, Katherine Tkaczuk, Agustin A. Garcia, Manmeet S. Ahluwalia, Jeffrey S. Wefel, Nehal Lakhani, Nuhad Ibrahim
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (12): 2789–2799.
https://doi.org/10.1158/1078-0432.CCR-19-3258
Published: 15 June 2020
View article titled, ANG1005, a Brain-Penetrating Peptide–Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases
Open the PDF for ANG1005, a Brain-Penetrating Peptide–Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases in another window